Inmazeb Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to past ebola outbreaks, high mortality rates, lack of effective treatments, global health emergency responses, regulatory fast track approvals.

The growth in the forecast period can be attributed to ongoing outbreak preparedness, expansion of infectious disease funding, improved surveillance systems, international health collaborations, investment in antiviral biologics. Major trends in the forecast period include rising demand for ebola therapeutics, government stockpiling of outbreak treatments, focus on combination antibody therapies, rapid deployment in emergency settings, strengthening global health preparedness.

The rising incidence of Ebola outbreaks is expected to drive the growth of the Inmazeb market in the future. Ebola virus disease (EVD) is a severe illness caused by ebolaviruses, typically transmitted from infected animals to humans, followed by human-to-human spread. The increasing frequency of Ebola outbreaks is largely due to factors such as environmental degradation, population mobility, and cultural practices that facilitate virus transmission. In addition, challenges in healthcare infrastructure and response measures complicate efforts to contain the virus effectively. As the number of outbreaks rises, so does the demand for Inmazeb, as there is an urgent need for effective treatment options to manage the increasing number of infections and provide timely care to affected populations. For example, in May 2024, the U.S. Centers for Disease Control and Prevention (CDC) reported that five out of six Ebola outbreaks were linked to the Sudan ebolavirus species. The most recent outbreak was declared over in January 2023, after 142 confirmed cases (plus 22 probable cases) and 55 confirmed fatalities. Therefore, the increasing frequency of Ebola outbreaks is contributing to the growth of the Inmazeb market.

The increase in investments in healthcare infrastructure is expected to drive the growth of the Inmazeb market in the coming years. Healthcare infrastructure encompasses the physical and organizational structures, facilities, systems, and workforce that collectively support healthcare service delivery and promote public health. The growing investments in healthcare infrastructure are driven by the need to improve service delivery, enhance health outcomes, and address the challenges exposed by the pandemic. These investments are improving the distribution and accessibility of Inmazeb, the first FDA-approved treatment for Ebola, ensuring that it reaches affected populations quickly during outbreaks. For example, in June 2025, HM Treasury, a UK-based government agency, reported that from 2023-24 to 2029-30, the Department of Health and Social Care’s (DHSC) annual capital budget will increase by £2.3 billion in real terms (a £4 billion cash rise) to support investments in NHS technology, hospitals, and primary care. This will result in the largest-ever health capital budget, with a real-term increase of over 20% by the end of the spending review period. As such, the growing investments in healthcare infrastructure are contributing to the growth of the Inmazeb market.

The expansion of drug access programs is also expected to drive the growth of the Inmazeb market in the future. Drug access programs provide patients with serious or life-threatening conditions the opportunity to access investigational medications or treatments that are not yet approved for general use, often outside of clinical trial settings, to address urgent medical needs when no satisfactory alternative therapies are available. The expansion of these programs is fueled by the need to offer investigational treatments to patients with no other satisfactory options and to bridge the gap between drug development and regulatory approval processes. These programs increase the availability of Inmazeb by facilitating access to the treatment during Ebola outbreaks, ensuring that patients can receive critical care when needed most. For example, in May 2024, the Department of Health and Social Care (DHSC) in the UK reported investing $670 million in naloxone access and treatment programs between 2022 and 2025, with the aim of preventing 1,000 drug-related deaths in England by 2025. As such, the expansion of drug access programs is playing a key role in driving the growth of the Inmazeb market.

Major companies operating in the inmazeb market are Regeneron Pharmaceuticals Inc.

North America was the largest region in the inmazeb market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inmazeb market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the inmazeb market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the inmazeb market by increasing costs of monoclonal antibody manufacturing inputs and cold chain logistics for emergency deployment. Public health programs and hospital segments in africa and north america are most affected due to reliance on imported biologics. These tariffs can complicate rapid outbreak response logistics. Conversely, tariffs are encouraging regional manufacturing partnerships and strengthening global emergency medical supply resilience.

The inmazeb market research report is one of a series of new reports that provides inmazeb market statistics, including inmazeb industry global market size, regional shares, competitors with a inmazeb market share, detailed inmazeb market segments, market trends and opportunities, and any further data you may need to thrive in the inmazeb industry. This inmazeb market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Inmazeb is a brand-name combination monoclonal antibody therapy (atoltivimab, maftivimab, and odesivimab-ebgn) designed to treat Zaire ebolavirus infection, commonly known as Ebola virus disease. The medication works by targeting the Ebola virus glycoprotein, neutralizing the virus, and preventing it from infecting cells. By using a combination of three antibodies, Inmazeb offers strong protection against the virus and supports the immune system in fighting the infection.

Inmazeb's primary applications are in treating Ebola virus disease and providing post-exposure prophylaxis. Ebola Virus Disease Treatment involves medical interventions focused on managing symptoms, aiding recovery, and reducing mortality in patients infected with the Ebola virus. It is used for treating various patient demographics, including pediatric patients, adult patients, and high-risk groups. Inmazeb is distributed through several channels, including hospitals, specialty clinics, and public health programs.

The inmazeb market consists of sales of atoltivimab, maftivimab, and odesivimab-ebgn. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.